Dr. David Barbie, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana Farber Cancer Institute

  Fellowship Hospital

• Massachusetts General Hospital

  Residency Hospital

• Harvard Medical School

  Medical School, 2002

• STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment, 2016-02-01

• Priming a vascular-selective cytokine response permits CD8+T-cell entry into tumors, 2023-04-14

• Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses, 2018-07-23

• Preclinical models for development of immune-oncology therapies, 2022-09-26

• Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies, 2022-07-22

• Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States, 2017-08-23

• Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated None-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure, 2018-08-04

• Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity, 2021-03-11

• CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation, 2017-11-03

• ER stress signaling promotes the survival of cancer ‘persister cells' tolerant to EGFR tyrosine kinase inhibitors, 2017-12-19

• MicroRNA-140mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6, 2017-01-16

• Phosphorylation of RAB7 by TBK1/IKKe Regulates Innate Immune Signaling in Triple Negative Breast Cancer, 2019-10-29

• Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer, 2021-11-22

• Targeting pathways downstream of KRAS in lung adenocarcinoma, 2014-11-04

• Activation of tumor-cell STING primes NK-cell therapy, 2022-08-03

• Inflammation as a Driver and Vulnerability of KRAS Mediated Oncogenesis, 2016-06-11

• Tumor cGAMP awakens the natural killers, 2018-10-16

• Long-term benefit of PD-L1 blockade in lung cancer associated withJAK3activation, 2015-05-26

• MPS1 inhibition primes immunogenicity ofKRAS-LKB1mutant lung cancer, 2022-09-22

• Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream ofKRAS, 2018-09-10

• MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer, 2022-11-02

• AKT-independent signaling downstream of oncogenicPIK3CAmutations in human cancer, 2009-07-07

• Systematic RNA interference reveals that oncogenicKRAS-driven cancers require TBK1, 2009-10-21

• Targeting Transcriptional Addictions In Small Cell Lung Cancer With a Covalent CDK7 Inhibitor, 2014-12-08

• Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer, 2019-08-15

• Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes, 2022-09-22

• Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancers, 2018-06-26

• Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit, 2014-01-20

• A robust vasculogenic microfluidic model using human immortalized endothelial cells and Thy1 positive fibroblasts, 2021-07-16

• Mechanisms of resistance to immune checkpoint inhibitors, 2018-01-02

• Targeting TBK1 to overcome resistance to cancer immunotherapy, 2023-01-12

• Tumor-Derived cGAMP Regulates Activation of the Vasculature, 2020-09-04

• Ex VivoProfiling of PD-1 Blockade Using Organotypic Tumor Spheroids, 2017-11-03

• Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation, 2016-04-11

• The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells, 2023-01-18

• Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer, 2023-08-15

• Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence, 2021-05-10

• Systematic interrogation of 3q26 identifiesTLOC1andSKILas cancer drivers, 2013-06-13

• A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade, 2018-11-01

• Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors, 2018-08-27

• Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment, 2016-08-19

• Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells, 2023-08-16

• Defining T cell states associated with response to checkpoint immunotherapy in melanoma, 2018-11-01

• Oncogenic switch and single-agent MET inhibitor sensitivity in a subset ofEGFR-mutant lung cancer, 2021-09-01

• Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation, 2015-02-07

• A Robust Method for Perfusable Microvascular Network Formation In Vitro, 2022-04-03

• Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer, 2018-10-08

• EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer, 2021-03-22

• Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies forHER2mutant non small cell lung cancer, 2020-02-07

• Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1, 2022-08-25

• 3D MicrofluidicEx VivoCulture of Organotypic Tumor Spheroids to Model Immune Checkpoint Blockade, 2018-10-09

• KRAS G12C inhibition and innate immune targeting, 2021-03-28

• RASA1/NF1mutant lung cancer: Racing to the clinic?, 2018-01-17

• Structure and ubiquitination-dependent activation of Tank-Binding Kinase 1, 2013-02-28

• Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade, 2022-11-08

• Inactivation ofFbxw7impairs dsRNA sensing and confers resistance to PD-1 blockade, 2020-05-05

• Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer, 2017-04-13

• Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway, 2020-01-13

• New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay, 2022-11-15

• A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing, 2018-09-21